Senile Dementia and Drug Therapy
As far as we can tell from the available literature, there are no specific drug therapies of major clinical benefit in senile dementia (Prien, 1973). Since the pathology of the condition has not been elucidated to the point of any specific remediable biochemical defect, specific therapy of the insulin — diabetes mellitus type has not been possible.
KeywordsCerebral Blood Flow Clinical Global Impression Ergot Alkaloid Senile Dementia Continuous Performance Test
Unable to display preview. Download preview PDF.
- Bouvier, J.B., Passeron, O. and Chapin, M.P. Psychometric study of praxilene. J. Int. Med. Res., 2:59–65, 1974.Google Scholar
- Cole, J. O., Branconnier, R.J. and Martin, G.F. Electroencephalogram and behavioral changes associated with papaverine administration in healthy geriatric subjects. J. Am. Geriatric Soc., 23:295–300, 1975.Google Scholar
- Fontaine, L., Brand, M., Charbert, J., Szavasi, E. and Bayssat, M. Cerebral pharmacology of a new vasodilatory drug, Naftidrofuryl. Bull. Chem. Ther., 6:463–469, 1968.Google Scholar
- Grauer, H. and Kral, V.A. The use of imipramine (tofranil) in psychiatric patients of a geriatric outpatient clinic. Con. Medical Association J., 83:1423–1426, 1960.Google Scholar
- Jarvik, L. F. and Milne, J. F. Gerovital-H3: A review of the literature. In: Aging Vol. 2, Genesis and treatment of psychologic disorders in the elderly, (edited by Gershon, S. and Raskin, A.), pp. 203–227, Raven Press, New York, 1975.Google Scholar
- Roubicek, J., Geiger, C. H. and Abt, K. An ergot alkaloid preparation (hydergine) in geriatric therapy. J. Am. Geriatric Soc., 20: 222–229, 1972.Google Scholar